Your browser doesn't support javascript.
loading
Evaluation of the maternal-fetal transfer of granisetron in an ex vivo placenta perfusion model.
Julius, Justin M; Tindall, Andrew; Moise, Kenneth J; Refuerzo, Jerrie S; Berens, Pamela D; Smith, Judith A.
  • Julius JM; Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Tindall A; Department of Gynecologic Oncology & Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Moise KJ; Department of Gynecology, Obstetrics & Reproductive Sciences, The University of Texas Health Sciences Center at Houston Medical School, Houston, TX, United States.
  • Refuerzo JS; Department of Gynecology, Obstetrics & Reproductive Sciences, The University of Texas Health Sciences Center at Houston Medical School, Houston, TX, United States.
  • Berens PD; Department of Gynecology, Obstetrics & Reproductive Sciences, The University of Texas Health Sciences Center at Houston Medical School, Houston, TX, United States.
  • Smith JA; Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX, United States; Department of Gynecologic Oncology & Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States; Department of Gynecology, Obstetrics & Reproductive
Reprod Toxicol ; 49: 43-7, 2014 Nov.
Article en En | MEDLINE | ID: mdl-25019977
ABSTRACT
The objective of this study was to estimate maternal-fetal transplacental passage of granisetron in an ex vivo placental perfusion model. Term human placentas (N=8) were collected immediately after delivery. A single cotyledon from each placenta was perfused granisetron concentration to mimic systemic maternal peak plasma concentrations following either IV (50ng/mL) or transdermal administration (5ng/mL). To assess drug transfer and accumulation, samples were collected from maternal and fetal compartments. In the 50ng/mL open model, the mean transport fraction was 0.21±0.08 with clearance index of 0.53±0.66. Fetal peak concentrations achieved was 5.6±6.6ng/mL with mean accumulation of 5.35±6.4ng/mL. No drug was detected in the fetal compartment with the 5ng/mL models. Transplacental passage of granisetron was inconsistent at the 50ng/mL concentration that achieved with IV dosing. However, there consistently was no detectable passage in all the placentas evaluated of the granisetron at 5ng/mL concentration that would be achieved after transdermal patch administration.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Granisetrón / Intercambio Materno-Fetal / Antieméticos Límite: Female / Humans / Pregnancy Idioma: En Año: 2014 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Granisetrón / Intercambio Materno-Fetal / Antieméticos Límite: Female / Humans / Pregnancy Idioma: En Año: 2014 Tipo del documento: Article